Literature DB >> 22150770

Algorithm for lamotrigine dose adjustment before, during, and after pregnancy.

A Sabers1.   

Abstract

BACKGROUND: Treatment with lamotrigine (LTG) during pregnancy is associated with a pronounced risk of seizure deterioration, because pregnancy accelerates LTG elimination. The extent to which pregnancy affects LTG pharmacokinetics is unpredictable and varies considerably among patients. AIM: We propose an algorithm for systematic LTG plasma concentration monitoring and dose adjustment to guide the clinician between the risk of seizure deterioration and LTG toxicity by maintaining a stable LTG concentration, using the optimal prepregnancy target concentration as a reference.
METHODS: The reference LTG plasma concentration (RC) should be determined before pregnancy or as early in pregnancy as possible. After conception, plasma concentration of LTG should be measured every 4 weeks throughout pregnancy. When the LTG plasma concentration falls below the RC, the dose of LTG should be increased by 20-25%. Post-partum, the plasma concentration of LTG should be measured within the first or second week, and if the LTG plasma concentration is higher than the RC, the LTG dose should be reduced by 20-25% and the procedure repeated until RC is re-established.
CONCLUSIONS: Seizure deterioration during pregnancy may be prevented or reduced by closely and systematically following our proposed algorithm.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22150770     DOI: 10.1111/j.1600-0404.2011.01627.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  7 in total

Review 1.  [Pharmacological treatment of women with epilepsy before and during pregnancy].

Authors:  B Müffelmann; C G Bien
Journal:  Nervenarzt       Date:  2016-10       Impact factor: 1.214

Review 2.  Pharmacogenetics and individualizing drug treatment during pregnancy.

Authors:  David M Haas
Journal:  Pharmacogenomics       Date:  2014-01       Impact factor: 2.533

Review 3.  Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring.

Authors:  Kristina M Deligiannidis; Nancy Byatt; Marlene P Freeman
Journal:  J Clin Psychopharmacol       Date:  2014-04       Impact factor: 3.153

Review 4.  Basic obstetric pharmacology.

Authors:  Yang Zhao; Mary F Hebert; Raman Venkataramanan
Journal:  Semin Perinatol       Date:  2014-10-01       Impact factor: 3.300

5.  Lamotrigine dosing for pregnant patients with bipolar disorder.

Authors:  Crystal T Clark; Autumn M Klein; James M Perel; Joseph Helsel; Katherine L Wisner
Journal:  Am J Psychiatry       Date:  2013-11       Impact factor: 18.112

6.  Pharmacokinetic changes and therapeutic drug monitoring of lamotrigine during pregnancy.

Authors:  Ye Ding; Xiaoping Tan; Shuo Zhang; Yang Guo
Journal:  Brain Behav       Date:  2019-05-18       Impact factor: 2.708

7.  Are doses of lamotrigine or levetiracetam adjusted during pregnancy?

Authors:  Noni Richards; David Reith; Michael Stitely; Alesha Smith
Journal:  Epilepsia Open       Date:  2017-11-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.